Format

Send to

Choose Destination
Clin Cancer Res. 2014 Jun 1;20(11):2817-9. doi: 10.1158/1078-0432.CCR-14-0576. Epub 2014 May 6.

The microenvironment matters: estrogen deficiency fuels cancer bone metastases.

Author information

1
Authors' Affiliations: Department of Medicine, Division of Endocrinology, Indiana University School of Medicine; and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
2
Authors' Affiliations: Department of Medicine, Division of Endocrinology, Indiana University School of Medicine; and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IndianaAuthors' Affiliations: Department of Medicine, Division of Endocrinology, Indiana University School of Medicine; and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana tguise@iu.edu.

Abstract

Factors released during osteoclastic bone resorption enhance disseminated breast cancer cell progression by stimulating invasiveness, growth, and a bone-resorptive phenotype in cancer cells. Postmenopausal bone loss may accelerate progression of breast cancer growth in bone, explaining the anticancer benefit of the bone-specific antiresorptive agent zoledronic acid in the postmenopausal setting. Clin Cancer Res; 20(11); 2817-9.

PMID:
24803577
PMCID:
PMC4061908
DOI:
10.1158/1078-0432.CCR-14-0576
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center